Much too risky for a partnership, if Phase III fails, what they have is worthless. No offense, you have been way off in your timing. Why should this be any different.
Well said, we are in the final stretch and this is about to become very interesting. Long shareholders will be rewarded for our long wait this will be a once in a lifetime event for all of us. Our lives will never be the same nor will all those patients that will benefit from this extraordinary drug. IMO
News 
Market Data 
Discover 
